Article
Endocrinology & Metabolism
Salvatore Grisanti, Deborah Cosentini, Marta Lagana, Alessandra Morandi, Barbara Lazzari, Laura Ferrari, Alberto Dalla Volta, Roberta Ambrosini, Vittorio Domenico Ferrari, Sandra Sigala, Alfredo Berruti
Summary: The Gem/Cape chemotherapy regimen shows modest activity in heavily pretreated patients with adrenocortical carcinoma. Clinical parameters such as neutrophil-to-lymphocyte ratio (NLR) and ECOG performance status are helpful in identifying patients who are unlikely to benefit significantly from this treatment.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Evelien J. M. de Jong, Quisette P. Janssen, Tessa F. A. Simons, Marc G. Besselink, Bert A. Bonsing, Stefan A. W. Bouwense, Sandra M. E. Geurts, Marjolein Y. Homs, Vincent E. de Meijer, Vivianne C. G. Tjan-Heijnen, Hanneke W. M. van Laarhoven, Liselot B. J. Valkenburg-van Iersel, Johanna W. Wilmink, Lydia G. van der Geest, Bas Groot Koerkamp, Judith de Vos-Geelen
Summary: In a nationwide cohort of patients with pancreatic ductal adenocarcinoma, adjuvant GEMCAP was associated with superior survival compared to GEM monotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Lanqi Ren, Ning Ren, Yu Zheng, Yibei Yang, Qiaoping Xu
Summary: This study analyzed the cost-effectiveness of neratinib plus capecitabine (N+C) and lapatinib plus capecitabine (L+C) in HER2-positive metastatic breast cancer. The results showed that N+C was dominant in most scenarios, providing an improvement of 0.17 quality-adjusted life-years (QALYs) and reducing costs compared to L+C. The ICER was below the willingness to pay threshold, indicating that N+C is a cost-effective third-line treatment option for HER2-positive metastatic breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Hyehyun Jeong, Kyu-pyo Kim, Jae Ho Jeong, Dae Wook Hwang, Jae Hoon Lee, Ki-Hun Kim, Deok-Bog Moon, Myung Ah Lee, Se Jun Park, Hong Jae Chon, Jin-hong Park, Ji Sung Lee, Baek-Yeol Ryoo, Changhoon Yoo
Summary: The effectiveness of adjuvant gemcitabine plus cisplatin (GemCis) therapy was evaluated in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma. The study found that adjuvant GemCis did not improve survival outcomes compared with capecitabine in this patient population.
Article
Oncology
Longjiang She, Kun Tian, Jiaqi Han, Weihan Zuo, Zhu Wang, Ning Zhang
Summary: Adding metronomic capecitabine to concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma patients has been shown to be a cost-effective strategy, resulting in additional quality-adjusted life years and a favorable incremental cost-effective ratio at a willingness-to-pay threshold of $33,585 per QALY.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
M. S. van der Heijden, G. Sonpavde, T. Powles, A. Necchi, M. Burotto, M. Schenker, J. P. Sade, A. Bamias, P. Beuzeboc, J. Bedke, J. Oldenburg, G. Chatta, Y. Urun, D. Ye, Z. He, B. P. Valderrama, J. H. Ku, Y. Tomita, J. Filian, L. Wang, D. Purcea, M. Y. Patel, F. Nasroulah, M. D. Galsky
Summary: In patients with previously untreated advanced urothelial carcinoma, combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes compared to gemcitabine-cisplatin alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Gunn Huh, Hee Seung Lee, Jin Ho Choi, Sang Hyub Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Seungmin Bang, Eaum Seok Lee
Summary: In patients with advanced pancreatic ductal adenocarcinoma after FOLFIRINOX failure, GnP demonstrated favorable efficacy with acceptable toxicity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Otorhinolaryngology
Zhen-Chong Yang, Chao-Chao Du, Ting Liu, Li-Ting Liu, Qiu-Yan Chen, Shan-Shan Guo, Hai-Qiang Mai
Summary: The study found significant differences in survival outcomes between patients treated with GP PCT within 2 years and 2 years after GP IC, as well as those receiving non-GP PCT.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Gastroenterology & Hepatology
Paula Ghaneh, Daniel Palmer, Silvia Cicconi, Richard Jackson, Christopher Michael Halloran, Charlotte Rawcliffe, Rajaram Sripadam, Somnath Mukherjee, Zahir Soonawalla, Jonathan Wadsley, Ahmed Al-Mukhtar, Euan Dickson, Janet Graham, Long Jiao, Harpreet S. Wasan, Iain S. Tait, Andreas Prachalias, Paul Ross, Juan W. Valle, Derek A. O'Reilly, Bilal Al-Sarireh, Sarah Gwynne, Irfan Ahmed, Kate Connolly, Kein-Long Yim, David Cunningham, Thomas Armstrong, Caroline Archer, Keith Roberts, Yuk Ting Ma, Christoph Springfeld, Christine Tjaden, Thilo Hackert, Markus W. Buchler, John P. Neoptolemos, European Study Group for Pancreatic Cancer European Study Grp Pancreat Canc
Summary: The study compared the feasibility and efficacy of three different types of short-course neoadjuvant therapy with immediate surgery. The findings showed that neoadjuvant chemotherapy significantly prolonged survival, with gemcitabine plus capecitabine or FOLFIRINOX regimen demonstrating the best results.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Ning Li, Yuan Zhu, Lu-Ying Liu, Yan-Ru Feng, Wen-Ling Wang, Jun Wang, Hao Wang, Gao-Feng Li, Yuan Tang, Chen Hu, Wen-Yang Liu, Hua Ren, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Yu Tang, Ning-Ning Lu, Bo Chen, Shu-Nan Qi, Xin-Fan Liu, Ye-Xiong Li, Jing Jin
Summary: The addition of oxaliplatin to postoperative capecitabine-based chemoradiotherapy did not improve treatment efficacy but increased the risk of severe acute toxic effects. Postoperative capecitabine with radiotherapy plays a fundamental role in the treatment of locally advanced rectal cancer.
Article
Oncology
Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho Jeong, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Bong Jun Kwak, Sarang Hong, Heung-Moon Chang, Baek-Yeol Ryoo, Kyu-pyo Kim, Song Cheol Kim
Summary: This retrospective study evaluated the efficacy and safety of GemCap versus Gem as adjuvant chemotherapy in an Asian population. The results showed that GemCap had better overall survival and consistent clinical outcomes compared to Gem. Further evaluation of optimal adjuvant chemotherapy is necessary due to the emergence of mFOLFIRINOX as the new standard treatment for resected PDAC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Li -Anne H. Douma, Ferry Lalezari, Vincent van der Noort, Jeltje F. de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A. Burgers, Cornedine J. de Gooijer
Summary: This study evaluated the clinical activity of pembrolizumab and lenvatinib combination therapy in patients with pleural mesothelioma. The results showed promising anti-tumor activity with considerable toxicity in this patient population, indicating the need for further investigation into the combination therapy.
Article
Oncology
Jing Jin, Yuan Tang, Chen Hu, Li-Ming Jiang, Jun Jiang, Ning Li, Wen-Yang Liu, Si-Lin Chen, Shuai Li, Ning-Ning Lu, Yong Cai, Yong-Heng Li, Yuan Zhu, Guang-Hui Cheng, Hong-Yan Zhang, Xin Wang, Su-Yu Zhu, Jun Wang, Gao-Feng Li, Jia-Lin Yang, Kuan Zhang, Yihebali Chi, Lin Yang, Hai-Tao Zhou, Ai-Ping Zhou, Shuang-Mei Zou, Hui Fang, Shu-Lian Wang, Hai-Zeng Zhang, Xi-Shan Wang, Li-Chun Wei, Wen-Ling Wang, Shi-Xin Liu, Yuan-Hong Gao, Ye-Xiong Li
Summary: This study aimed to compare the efficacy of preoperative short-term radiotherapy followed by chemotherapy with a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer. The results showed that the short-term radiotherapy and chemotherapy regimen was non-inferior to the standard regimen in terms of 3-year disease-free survival and had better overall survival.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ruijia Chen, Yalan Zhang, Kongying Lin, Defu Huang, MaoJin You, Yanjin Lai, Jinye Wang, Yingying Hu, Na Li
Summary: From the perspective of the Chinese healthcare system, XELOX is a more cost-effective first-line treatment for advanced biliary tract cancers compared to GEMOX.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
David Malka, Benjamin Verret, Matthieu Faron, Rosine Guimbaud, Caroline Caramella, Julien Edeline, Marie-Pierre Galais, Leila Bengrine-Lefevre, Denis Smith, Eric Dupont-Bierre, Thierry De Baere, Diane Goere, Peggy Dartigues, Ludovic Lacroix, Maximiliano Gelli, Jean-Pierre Pignon, Michel Ducreux
Summary: HAI oxaliplatin plus systemic 5-fluorouracil and cetuximab is highly effective as frontline treatment for patients with unresectable CRLM and is well-tolerated.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Cell Biology
Antonina Germano, Daniela Rossin, Valerio Leoni, Noemi Iaia, Laura Saba, Vittoria Basile, Soraya Puglisi, Claudio Caccia, Giuseppe Poli, Fiorella Biasi, Massimo Terzolo
Article
Oncology
Vittoria Basile, Soraya Puglisi, Anna Calabrese, Anna Pia, Paola Perotti, Alfredo Berruti, Giuseppe Reimondo, Massimo Terzolo
Article
Health Care Sciences & Services
Vittoria Basile, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libe, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti, Paola Berchialla, Ulrich Dischinger, Felix Megerle, Eric Baudin, Isabelle Bourdeau, Andre Lacroix, Paola Loli, Alfredo Berruti, Darko Kastelan, Harm R. Haak, Martin Fassnacht, Massimo Terzolo
Summary: The study found that extending adjuvant mitotane treatment over two years did not show significant survival advantage in patients with ACC, and the relationship between treatment duration and the frequency of ACC recurrence was not linear.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Health Care Sciences & Services
Marco Volante, Ida Rapa, Jasna Metovic, Francesca Napoli, Cristian Tampieri, Eleonora Duregon, Massimo Terzolo, Mauro Papotti
Summary: This study identified dysregulation of 14 genes in adrenocortical carcinomas, with most being downregulated. However, three exceptions showed increased expression levels, including HAS-1, laminin alpha 3, and osteopontin genes, which could serve as potential diagnostic and prognostic biomarkers in adrenal cortical tumors.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Letizia Canu, Soraya Puglisi, Paola Berchialla, Giuseppina De Filpo, Francesca Brignardello, Francesca Schiavi, Alfonso Massimiliano Ferrara, Stefania Zovato, Michaela Luconi, Anna Pia, Marialuisa Appetecchia, Emanuela Arvat, Claudio Letizia, Mauro Maccario, Mirko Parasiliti-Caprino, Barbara Altieri, Antongiulio Faggiano, Roberta Modica, Valentina Morelli, Maura Arosio, Uberta Verga, Micaela Pellegrino, Luigi Petramala, Antonio Concistre, Paola Razzore, Tonino Ercolino, Elena Rapizzi, Mario Maggi, Antonio Stigliano, Jacopo Burrello, Massimo Terzolo, Giuseppe Opocher, Massimo Mannelli, Giuseppe Reimondo
Summary: This study was the first to assess the risk of developing a second malignant tumor in PPGL patients, showing that they have a higher incidence of additional malignant tumors compared to the general population who had a first malignancy. The main tumors associated with second malignancies differed by gender, with an impact on surveillance strategy.
Review
Oncology
Marco Lo Iacono, Soraya Puglisi, Paola Perotti, Laura Saba, Jessica Petiti, Claudia Giachino, Giuseppe Reimondo, Massimo Terzolo
Summary: Mitotane is the only approved drug for the treatment of advanced adrenocortical carcinoma and is increasingly used for postoperative adjuvant therapy. It destroys the adrenal cortex, impairs steroidogenesis, and leads to cell death by deregulating cytochromes P450 enzymes, depolarizing mitochondrial membranes, and accumulating free cholesterol. The exact mechanism of mitotane's action is still unclear, and the variability in in vitro experimental conditions could impact the significance of identified molecular mechanisms.
Article
Oncology
Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Groeschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herraez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina Gotze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Steven Attia
Summary: The clinical benefit of Selinexor in patients with advanced DD-LPS has been evaluated. The results showed that Selinexor improved PFS and time to next treatment compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mirko Parasiliti-Caprino, Fabio Bioletto, Chiara Lopez, Martina Bollati, Francesca Maletta, Marina Caputo, Valentina Gasco, Antonio La Grotta, Paolo Limone, Giorgio Borretta, Marco Volante, Mauro Papotti, Anna Pia, Massimo Terzolo, Mario Morino, Barbara Pasini, Franco Veglio, Ezio Ghigo, Emanuela Arvat, Mauro Maccario
Summary: This study aimed to develop a simplified scoring system to help assess the recurrence risk of pheochromocytoma patients after surgery. Analysis of previous data revealed tumor size, genetic testing result, age, and PASS value as independent variables associated with recurrence.
Article
Biology
Silvia De Francia, Alessandro Ferretti, Francesco Chiara, Sarah Allegra, Daniele Mancardi, Tiziano Giacomo Allice, Maria Grazia Milia, Gabriella Gregori, Elisa Burdino, Claudio Avanzini, Valeria Ghisetti, Alessandra Durio
Summary: Sex and gender differences play an important role in the clinical manifestation of diseases, particularly in the context of the COVID-19 pandemic. Women have a stronger immune system compared to men, resulting in milder symptoms. Additionally, women are more likely to practice social distancing and smoke less. Analyses of testing data from Amedeo di Savoia Hospital in 2020 indicate that taking a sex and gender-based approach is crucial for patients and the sustainability of the National Health System.
Review
Endocrinology & Metabolism
Massimo Terzolo, Martin Fassnacht
Summary: Surgery remains the most important therapeutic option for non-metastatic ACC, with the surgeon's expertise being more important than surgical technique. For patients at low risk of recurrence, active surveillance can spare them from unnecessary adjuvant mitotane treatment, while those at moderate-to-high risk should ideally enroll in the ongoing ADIUVO2 trial. Prospective multicenter trials are needed for long-term improvement of patient care.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Oncology
Bruno Vincenzi, Andrea Napolitano, Alessandro Comandone, Roberta Sanfilippo, Simone Celant, Pier P. Olimpieri, Susanna Di Segni, Pierluigi Russo, Paolo G. Casali
Summary: This study analyzed the use of trabectedin in Italian patients with soft-tissue sarcomas and found that trabectedin is effective in treating leiomyosarcoma and liposarcoma patients.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica T. Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel L. Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo A. Ascierto, Corrado Ficorella, David J. Pinato
Summary: The impact of type 2 diabetes mellitus (T2DM) on the clinical outcome of immune checkpoint inhibitors (ICI) in solid tumor patients is uncertain. Patients on glucose-lowering medications (GLM) for T2DM had worse overall survival (OS) and progression-free survival (PFS) independent of the number of GLM received. Among the GLM, metformin use was associated with increased risk of death and disease progression/death. Further studies are needed to understand the relative impact of metformin and preexisting T2DM diagnosis on outcomes in this population.
CLINICAL CANCER RESEARCH
(2023)
Article
Endocrinology & Metabolism
Martin Fassnacht, Stylianos Tsagarakis, Massimo Terzolo, Antoine Tabarin, Anju Sahdev, John Newell-Price, Iris Pelsma, Ljiljana Marina, Kerstin Lorenz, Irina Bancos, Wiebke Arlt, Olaf M. Dekkers
Summary: Adrenal incidentalomas are adrenal masses detected on imaging for non-suspected adrenal disease. A revision of the first international guidelines on incidentalomas has been provided, focusing on assessing risk of malignancy, managing mild autonomous cortisol secretion, deciding surgical treatment, and determining follow-up for nonoperated patients. Key recommendations include dedicated adrenal imaging for each adrenal mass, thorough clinical and endocrine work-up to exclude hormone excess, consideration of surgical treatment for patients with mild autonomous cortisol secretion and relevant comorbidities, and appropriate surgical intervention guided by risk of malignancy and hormone excess.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Editorial Material
Biology
Silvia De Francia, Francesco Chiara, Sarah Allegra
Article
Biochemistry & Molecular Biology
Sarah Allegra, Emma Dondi, Francesco Chiara, Silvia De Francia
Summary: This study examined the influence of age and sex on the levels of tyrosine kinase inhibitors in plasma and cerebrospinal fluid of patients with chronic myeloid leukaemia. Results showed an inverse correlation between age and imatinib plasma concentration, and lower dasatinib concentrations in plasma compared to cerebrospinal fluid, especially in paediatric patients. Therapeutic drug monitoring, along with tyrosine kinase inhibitors, is supported for the treatment of chronic myeloid leukaemia. Refinement of the classification of tyrosine kinase inhibitor therapeutic drug monitoring should consider factors like sex and age.